Ask AI
Back Back
Steve Ubl Steps Down from PhRMA Amid Drug Pricing Pressure
Activity Information Ask a Question

Activity

Progress
1
Course Completed
Activity Information

Released: April 29, 2026

John Marshall
John Marshall, MD
 
Catch Up On All Episodes of Oncology Unscripted

Watch Now

MedBuzz: Steve Ubl Steps Down From PhRMA Amid Drug Pricing Pressure

[00:00:08]

John Marshall, MD: Hey, everybody out there. John Marshall for Oncology Unscripted. Thanks for joining us again. We hope that you're getting something out of all of this stuff that we're putting out there. We're focusing on AI, but first, we've got to talk about the news of the week, and to me, the biggest news is that there's this guy named Steve Ubl—U B L.

You may not even know Steve Ubl, but you probably know of him. He was the head, a CEO of PhRMA, which is the big lobbying group for big pharmaceutical companies. They're down on K Street or down in Washington, and they have had a major influence over everything we've done in cancer, and frankly, medicine in general, with the support of the pharmaceutical industry.

The most recent tension, and we talked about this before on Oncology Unscripted, is the rising price of drugs and the fact that only certain parts of the world can afford those medicines, and many parts of the world cannot because of the high prices that are set here in the United States, and that our insurance does pay for it and Medicare will pay for it, et cetera.

So, there's this sort of business industry that's around drugs and drug pricing that the previous administration, the Biden administration, and the current administration want to undo, right? You've seen ads if you're in any market like mine here in Washington, where there's a lot of finger-pointing as to whose fault it is that drugs are so expensive. Trump has put tariffs on imported drugs, which has threatened this business model, and we know we are all living off of this business model. But the reason I think Steve Ubl stepping down as CEO of PhRMA is such a big deal is, you know, he's an important figure in what is the existing structure.

We'll see what this means going forward. Is this a sign that there's going to be a shift in the policy at the level of PhRMA and, you know, government interface? Or is it because of pressure? Is it that his job has gotten to be no more fun and he wants to do something different? I don't know yet, but this was just announced today. So, keep your nose out for the changes that are occurring in the relationship between the pharmaceutical industry, the payer, and the patient as we go forward through the year of 2026 in the current administration.

Stay tuned. John Marshall, Oncology Unscripted.

This transcript was originally generated by AI and lightly edited for clarity.